2 weeks Ago By ABMN Staff
Main Management Fund Advisors LLC lifted its holdings in SPDR S&P Biotech ETF ( NYSEARCA:XBI – Free Report ) by 8.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 598,200 shares of the exchange traded fund’s stock after purchasing an additional 45,700 shares during the quarter.
SPDR S&P Biotech ETF accounts for approximately 10.0% of Main Management Fund Advisors LLC’s investment portfolio, making the stock its 4th biggest holding. Main Management Fund Advisors LLC’s holdings in SPDR S&P Biotech ETF were worth $55,459,000 at the end of the most recent quarter.
Several other large investors have also added to or reduced their stakes in the business. Dimension Capital Management LLC increased its position in shares of SPDR S&P Biotech ETF by 28.5% in the second quarter.
Dimension Capital Management LLC now owns 15,311 shares of the exchange traded fund’s stock valued at $1,419,000 after acquiring an additional 3,396 shares during the last quarter. Employees Retirement System of Texas grew its stake in SPDR S&P Biotech ETF by 40.8% in the second quarter.
Employees Retirement System of Texas now owns 603,857 shares of the exchange traded fund’s stock valued at $55,984,000 after purchasing an additional 174,857 shares in the last quarter. Affinity Asset Advisors LLC grew its stake in shares of SPDR S&P Biotech ETF by 105.4% in the second quarter.
Affinity Asset Advisors LLC now owns 37,550 shares of the exchange traded fund’s stock valued at $3,481,000 after buying an additional 737,550 shares in the last quarter. Prairie Wealth Advisors Inc. raised its position in SPDR S&P Biotech ETF by 3.
6% during the second quarter. Prairie Wealth Advisors Inc. now owns 6,616 shares of the exchange traded fund’s stock worth $613,000 after acquiring an additional 231 shares in the last quarter.
Finally, Toronto Dominion Bank lifted its stake in SPDR S&P Biotech ETF by 16.3% in the second quarter. Toronto Dominion Bank now owns 21,743 shares of the exchange traded fund’s stock valued at $2,016,000 after acquiring an additional 3,048 shares during the last quarter.
SPDR S&P Biotech ETF Price Performance SPDR S&P Biotech ETF stock opened at $98.43 on Friday. The company’s 50-day moving average is $98.
94 and its 200-day moving average is $93.97. The firm has a market capitalization of $7.
50 billion, a PE ratio of 11.47 and a beta of 1.11.
SPDR S&P Biotech ETF has a fifty-two week low of $63.80 and a fifty-two week high of $103.52.
SPDR S&P Biotech ETF Profile SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Further Reading Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF ( NYSEARCA:XBI – Free Report ). Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.
com's FREE daily email newsletter ..
